Concomitant microRNA-31 downregulation and radixin upregulation predicts advanced tumor progression and unfavorable prognosis in patients with gliomas

详细信息    查看全文

• 作者：Shuai Wang ; Baohua Jiao ; Shaomei Geng ; Jian Song ; Zhaohui Liang ; Shengkui Lu ; ^{lskhbey@163.com" class="auth_mail}
• 关键词：MicroRNA-31 ; Radixin ; Glioma ; Expression ; Clinicopathologic characteristics ; Prognosis
• 刊名：Journal of the Neurological Sciences
• 出版年：15 March, 2014
• 年：2014
• 卷：338
• 期：1-2
• 页码：71-76
• 全文大小：479 K

文摘

Purpose

To clarify the clinical significance of microRNA-31 (miR-31) and radixin (RDX) in human glioma.

Methods

Quantitative real-time polymerase chain reaction (qRT-PCR) analysis was used to characterize the expression patterns of miR-31 and RDX mRNA in 108 glioma and 20 normal brain tissues. The associations of miR-31 and RDX mRNA expressions with clinicopathologic factors and prognosis of glioma patients were also statistically analyzed.

Results

The expression levels of miR-31 in glioma tissues were significantly lower than those in normal brain tissues (P < 0.001), while RDX mRNA was significantly overexpressed in glioma tissues compared with normal brain tissues (P < 0.001). There was a negative correlation between miR-31 and RDX mRNA expression in glioma tissues (r = 鈭?#xA0;0.69, P = 0.01). Additionally, concomitant miR-31 downregulation and RDX upregulation (miR-31-low/RDX-high) was significantly associated with advanced pathological grade (P = 0.001) and low Karnofsky performance score (P = 0.01). Moreover, Kaplan-Meier survival and Cox regression analyses showed that the glioma patients with miR-31-low/RDX-high expression had poorest overall survival (P < 0.001) and conjoined expression of miR-31-low/RDX-high was an independent prognostic indicator of glioma (P = 0.01). Furthermore, subgroup analyses showed that miR-31-low/RDX-high expression was significantly associated with poor overall survival in glioma patients with high pathological grades (for grade III-IV: P < 0.001).

Conclusions

Our findings have implications concerning the importance of concomitant miR-31 downregulation and RDX upregulation in tumor progression and poor prognosis of patients with gliomas. A combined detection of miR-31/RDX expression may benefit us in predicting clinical outcomes of glioma patients with high pathological grades.